Mass drug administration for malaria
Administration of antimalarial drugs to whole populations (mass drug administration) can reduce the initial (6 month) risk of malaria-specific outcomes, but few studies found that this effect was sustained. However, adverse events were inadequately addressed in these studies.
Malaria is the most important mosquito-borne disease caused by a parasite, accounting for an estimated 660,000 deaths annually. Fortunately, malaria is both preventable and treatable. The review aimed to assess the potential for mass drug administration to reduce malaria burden and transmission, and to identify gaps in our understanding. It highlighted that such reviews are a challenge due to the heterogeneity of the study methods employed.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.